title: Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry.
abstract: BACKGROUND
  Primary percutaneous coronary intervention (PCI) is the preferred method of reperfusion in patients with ST elevation myocardial infarction (STEMI). Abciximab is a well established adjunct to primary PCI. The proper timing of abciximab administration in STEMI patients has been investigated in randomised trials, registries and metanalysis, providing conflicting results.
  
  
  METHODS
  Consecutive data on STEMI patients, transferred for primary PCI in hospital/ambulance STEMI networks between November 2005 and January 2007, from 15 PCI centres in seven European countries was gathered together for a one-year long-term clinical observation (93% rate of completeness).
  
  
  RESULTS
  Data from 1,650 patients was collected in the EUROTRANSFER Registry. Abciximab was administered to 1,086 patients (66%), 727 patients received early (at least 30 minutes prior to first balloon inflation) abciximab (EA), and another 359 patients received late abciximab (LA). One year mortality was 5.8% in the EA group vs 10.3% with LA (p = 0.007). Adjustment for propensity score methods for EA administration did not change the results, still providing a favourable outcome for the EA group (p = 0.004). It was also revealed that only a minority of patients (36%) were treated within the 90-minute recommended time window from first medical contact to PCI (and 60% for the 120-min time delay).
  
  
  CONCLUSIONS
  Patients transferred for primary PCI in STEMI hospital networks showed lower rates of death in long-term one-year clinical follow-up when treatment with abciximab was started early.
authors.affiliation: Institute of Cardiology, Collegium Medicum, Jagiellonian University, Krakow, Poland. zbigniew.siudak@gmail.com
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Siudak
authors.forename: Tomasz
authors.initials: T
authors.lastname: Rakowski
authors.forename: Artur
authors.initials: A
authors.lastname: Dziewierz
authors.forename: Magnus
authors.initials: M
authors.lastname: Janzon
authors.forename: Ralf
authors.initials: R
authors.lastname: Birkemeyer
authors.forename: Justyna
authors.initials: J
authors.lastname: Stefaniak
authors.forename: Łukasz
authors.initials: Ł
authors.lastname: Partyka
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Zmudka
authors.forename: Dariusz
authors.initials: D
authors.lastname: Dudek
mesh_terms: D000077284:Abciximab; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004562:Electrocardiography; D005060:Europe / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D012042:Registries / Q000706:statistics & numerical data*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab